Concordia Healthcare Corp (CXRX) : Taylor Asset Management Inc scooped up 655,000 additional shares in Concordia Healthcare Corp during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 25, 2016. The investment management firm now holds a total of 923,400 shares of Concordia Healthcare Corp which is valued at $16,815,114.Concordia Healthcare Corp makes up approximately 4.67% of Taylor Asset Management Inc’s portfolio.
Other Hedge Funds, Including , Davis-rea Ltd. boosted its stake in CXRX in the latest quarter, The investment management firm added 221,502 additional shares and now holds a total of 367,647 shares of Concordia Healthcare Corp which is valued at $7,158,087. Concordia Healthcare Corp makes up approx 4.63% of Davis-rea Ltd.’s portfolio. Simplex Trading added CXRX to its portfolio by purchasing 5,875 company shares during the most recent quarter which is valued at $122,964. Concordia Healthcare Corp makes up approx 0.02% of Simplex Trading’s portfolio.Cutler Group Lp boosted its stake in CXRX in the latest quarter, The investment management firm added 1,965 additional shares and now holds a total of 7,815 shares of Concordia Healthcare Corp which is valued at $160,286. Concordia Healthcare Corp makes up approx 0.01% of Cutler Group Lp’s portfolio.
On the company’s financial health, Concordia Healthcare Corp reported $1.35 EPS for the quarter, missing the analyst consensus estimate by $ -0.05 based on the information available during the earnings call on May 13, 2016. Analyst had a consensus of $1.40. The company had revenue of $228.50 million for the quarter, compared to analysts expectations of $228.07 million. The company’s revenue was up 570.1% compared to the same quarter last year.
Many Wall Street Analysts have commented on Concordia Healthcare Corp. Concordia Healthcare Corp was Initiated by Goldman to “Neutral” on Jun 6, 2016.
Concordia Healthcare Corp. is a Canada-based diverse healthcare company. The Company is focused on legacy pharmaceutical products and orphan drugs. The Company operates through three segments which includes Legacy Pharmaceutical Division Concordia Pharmaceuticals Inc. which consists of 23 products including Nilandron for the treatment of metastatic prostate cancer; Dibenzyline for the treatment of pheochromocytoma; Lanoxin for the treatment of mild-to-moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; Donnatal for the treatment of irritable bowel syndrome and Zonegran (zonisamide) for treatment of partial seizures in adults with epilepsy. Its Specialty Healthcare Distribution (SHD) Division Complete Medical Homecare is engaged in the distribution of medical supplies focused on diabetes and related conditions. Its Orphan Drugs Division Concordia Laboratories Inc. is engaged in the manufacture of PHOTOFRIN.